Navigation Links
New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
Date:9/21/2011

uent in patients receiving 150 mg of BIBF 1120 twice daily than placebo and adverse events leading to discontinuation were mostly diarrhea, nausea and vomiting.

"People who suffer from IPF are in great need of a safe and effective treatment to preserve lung function so they can maintain physical activity and reduce the impact on their independence for as long as possible," said Luca Richeldi, MD, PhD, lead study author and director of the Research Centre for Rare Lung Diseases, University of Modena and Reggio Emilia, Modena, Italy. "The positive trends in slowing the decline in lung function over time, reducing the incidence of acute exacerbations and improving the quality of life with BIBF 1120 are a promising proof of concept."

BIBF 1120 received orphan-drug designation from the U.S. Food and Drug Administration in June 2011. Two pivotal phase III clinical trials are currently underway enrolling a total of 970 patients in 20 countries. The first patients entered the trials in April and May 2011, respectively. For more information about the phase III trials or to learn how to enroll, please visit clinicaltrials.gov (identifiers NCT01335464 and NCT01335477).

"The results of the phase II clinical trial for BIBF 1120 in IPF give us the confidence to continue assessing the compound's potential in phase III clinical trials," said Christopher Corsico, MD, MPH, senior vice president, Medicine and Regulatory, North America, Boehringer Ingelheim Pharmaceuticals, Inc. "Boehringer Ingelheim remains committed to identifying an effective treatment for IPF to help bridge the unmet therapeutic need for the thousands of people suffering from this fatal disease."

TOMORROW Data at ERS 2011 Annual Congress

The NEJM paper will be presented at the European Respiratory Society (ERS) 2011 Annual Congress on Monday, Sept. 26, 2011. Additional results of the TOMORROW trial will be presented during oral sessions at ERS on Sunday, Sept. 25, 2
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lung Cancer Study Reveals Similar Outcomes for African-American and Caucasian Patients Treated With Alimta®
2. Studying Fluid Overflow in Patients With Devices
3. Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
4. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
5. Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
6. The 62nd Annual Meeting of the American Association for the Study of Liver Diseases
7. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
8. First Patient Enrolled in SARcode Biosciences Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution
9. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
10. Breast Health Study Advances Safety Profile for Soy-Based Natural S-equol Supplement Designed to Manage Menopause Symptoms
11. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... REDMOND, Washington , 29. Juli 2015 ... deutschen Diabeteszentrums wurde festgestellt, dass die tägliche ... von Nutraceutix die menschliche Darmflora anreichert und ... Insulinsekretion erhöhen. Die Studie umfasste die tägliche ... (ATCC-Stamm SD-5865) in Tablettenform unter Verwendung der ...
(Date:7/29/2015)... 2015  PDL BioPharma, Inc. (NASDAQ: PDLI ) ... interest assignment agreement (the "Agreement") in which it has ... ) with up to $200 million in revenue interest ... of Iclusig ® (ponatinib).  Funding of the first ... $50 million each, with the initial amount having already ...
(Date:7/29/2015)... Touro College has announced that it is supporting ... of five media marijuana licenses to be issued by the ... (DOH).  If CanniCare is selected, Touro would ... "Our college is supportive of medicinal development and research," ... College System. "There is still a great deal of research ...
Breaking Medicine Technology:Klinischer Nachweis erbracht, dass L. reuteri Probiotikum von Nutraceutix den Darm-Insulinmetabolismus moduliert 2PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 2PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 3PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 4PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 5Touro College Announces Support for CanniCare's Medical Cannabis License Application 2
... 2011 Curemark, LLC , ( www.curemark.com ), a ... neurological diseases, announced that the company has completed its targeted ... its autism treatment. Curemark has reached its targeted ... are participating in the CM-AT Phase III trial at 18 ...
... 2011 Echo Therapeutics, Inc. (OTC Bulletin Board: ... tCGM System as a non-invasive, wireless, transdermal continuous glucose ... transdermal drug delivery, today announced results for the year ... 10-K is available through Echo,s website at www.echotx.com ...
Cached Medicine Technology:Curemark Completes Enrollment of Phase III Autism Trials 2Echo Therapeutics Announces 2010 Financial Results 2Echo Therapeutics Announces 2010 Financial Results 3Echo Therapeutics Announces 2010 Financial Results 4
(Date:7/29/2015)... ... July 29, 2015 , ... ... that Columbia University Medical Center, located in New York, NY, selected the ReadyCam ... easy for physicians and scientists to immediately access worldwide TV and cable news ...
(Date:7/29/2015)... ... July 29, 2015 , ... Abt Associates has named ... Health division. In her position, Ramkeesoon will help build and expand work ... Ramkeesoon spent close to a decade at ICF International, most recently as a ...
(Date:7/29/2015)... ... 29, 2015 , ... Andrzej Klos, M.D., has been reviewed and approved as ... 38 years, is motivated each and every day by his sincere desire to help ... his many awards and accolades, which include multiple listings in many highly regarded medical ...
(Date:7/29/2015)... ... 29, 2015 , ... Today the nonprofit Alliance for ... Vaccination in Older Adults, that provides a comprehensive overview of the factors that ... health care experts can improve patient compliance. , Although influenza, pneumococcal, tetanus, and ...
(Date:7/29/2015)... ... , ... " Core Organizer ” was featured on NewsWatch as part of ... the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and ... help anyone get organized. , Wouldn’t it be great if everyone could be a ...
Breaking Medicine News(10 mins):Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 2Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 3Health News:Selena Ramkeesoon Joins Abt Associates as Vice President for Strategic Communications 2Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 2Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 3Health News:Vaccination Rates in Older Adults Fall Short of Targets 2Health News:Vaccination Rates in Older Adults Fall Short of Targets 3Health News:Get More Organized with the Core Organizer App 2
... Health and the University of Colorado Denver have discovered a ... acute lung injury. Acute lung injury (ALI) is often caused ... in the blood, and fluid in the lungs. It is ... afflicting almost 200,000 people in the United States each year, ...
... Pharos Innovations, a pioneer in,assisting clients to ... a device-free remote monitoring platform,today announced it is ... of two key appointments in medical informatics and ... http://www.newscom.com/cgi-bin/prnh/20080306/AQTH086LOGO ) , ...
... N.Y., Jan. 16 Bausch & Lomb, the ... Valenti, III, will join Bausch & Lomb as ... month."Pete possesses deep leadership experience, as well as ... Stuart Heap, corporate vice president and global president, ...
... 16 /PRNewswire-FirstCall/ - Thomas E. Gardner, Chairman, announced ... appointed to the NUCRYST Pharmaceuticals, Board of Directors. ... Executive Officer of The Westaim Corporation ("Westaim"), NUCRYST,s ... common shares. Prior to his appointment as President ...
... 16 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... of medical devices worldwide, today announced updates on ... and international markets in,2009. , ... of ten products, achieving the goals,for new product ...
... in Guangdong ProvincePROVO, Utah, Jan. 15 Nu Skin ... that it has received official notification from the Chinese ... selling activities in four cities in the Guangdong province ... Skin Enterprises the opportunity to offer a direct selling ...
Cached Medicine News:Health News:Gene associated with reduced mortality from acute lung injury 2Health News:Pharos Innovations Strengthens Leadership Team, Informatics Program 2Health News:Pharos Innovations Strengthens Leadership Team, Informatics Program 3Health News:Bausch & Lomb Names Peter Valenti, III, as President, North America, Vision Care 2Health News:NUCRYST Pharmaceuticals appoints a new director 2Health News:NUCRYST Pharmaceuticals appoints a new director 3Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 2Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 3Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 4Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 5Health News:Nu Skin Enterprises Receives Broader Direct Selling Authorization in China 2
... relieve low back discomfort. Strong mesh elastic ... comfortable, custom fit. Optional metal stays may ... spine. Wide elastic adjustment panels provide varying ... easily accessed and adjusted. Simple hood and ...
... Newport® Hip Management Systems are designed and ... orthosis for your patients. Innovative new options ... is built on the most successful patented ... the adjustable clamping disk design and the ...
... Pelvic Brace is the solution to the ... off-the-shelf brace fits like a custom and ... minutes. The Bledsoe Simple Pelvic Brace limits ... and adduction in 15 increments from -30 ...
... Abduction and rotation for ... and fractures. Preset at ... adjustable flexion and extension ... back panel. Available in ...
Medicine Products: